Research programme: vaginal infections therapeutics - Catalent
Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Columbia Laboratories
- Developer Catalent
- Class Amides; Anti-infectives; Antiacnes; Oxidants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vaginitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vaginitis in USA (Vaginal)
- 01 Apr 2015 Columbia Laboratories is now called Juniper Pharmaceuticals
- 31 Dec 2008 Preclinical trials in Vaginitis in USA (Vaginal)